NCT05540457

Brief Summary

Prospective, single center, open label, non-randomized, post-market study of the Tablo Hemodialysis System and VitalStream Monitor in participants with End-Stage KidneyDisease undergoing In-Center Hemodialysis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 14, 2022

Completed
8 days until next milestone

Study Start

First participant enrolled

September 22, 2022

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 9, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 9, 2024

Completed
Last Updated

June 11, 2025

Status Verified

June 1, 2025

Enrollment Period

1.4 years

First QC Date

August 10, 2022

Last Update Submit

June 9, 2025

Conditions

Keywords

TabloOutset Medical, Inc.Caretaker Medical, LLCVitalStreamESKD

Outcome Measures

Primary Outcomes (1)

  • Non-invasive Blood Pressure Monitor (NIPB) Measurements

    Correlation of BP measurements (e.g., systolic, diastolic, mean arterial,and pulse pressures) between NIPB monitors.

    7 days from start of participation

Secondary Outcomes (2)

  • Intradialytic Blood Pressure Events

    7 days from start of participation

  • Participant Preference for the Non-invasive Blood Pressure Monitor (NIPB)

    7 days from start of participation

Study Arms (1)

Non-Invasive Blood Pressure (NIPB)Monitors

EXPERIMENTAL

NIPB Tablo Brachial Cuff (Intermittent): Will be placed contralateral to the access arm. Blood pressure measurements will be collected pre-dialysis, every 30minutes during dialysis, and post-dialysis. VitalStream Monitor (Continuous):A cuff will be applied to the middlefinger ipsilateral to the accessarm. Blood pressuremeasurements will be collectedpre-dialysis, continuously duringdialysis, and post-dialysis.

Device: Intermittent Non-InvasiveBlood Pressure Monitor

Interventions

Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis. Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis.

Non-Invasive Blood Pressure (NIPB)Monitors

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participant is at least 18 years of age and has provided informed consent and has signed a Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant authorization statement.
  • Participant weighs ≥ 34kg.
  • Participant has end stage kidney disease (ESKD) adequately treated by maintenance dialysis.

You may not qualify if:

  • Participant has lack of perfusion of the digitalarteries and arterioles in the lower arm and hand.
  • The Non-Invasive Blood Pressure (NIPB) monitorcuffs (finger and/or brachial) are unable to becorrectly sized to the participant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Rogosin Institute

New York, New York, 10019, United States

Location

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Frank Liu, MD

    The Rogosin Institute, Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2022

First Posted

September 14, 2022

Study Start

September 22, 2022

Primary Completion

February 9, 2024

Study Completion

February 9, 2024

Last Updated

June 11, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations